Device Trial Radar · NCT07128316
LASIK Using Contoura With Phorcides vs. iDesign
Last checked: Nov 20, 2026Latest source record: Aug 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
63
Planned (sponsor's estimate)
Start
Sep 11, 2023
Primary completion
Dec 15, 2025
Study completion Dec 15, 2025
Sponsor
- Lead sponsor
- 59th Medical WingFederal agency
- Sponsor type
- Federal agency
- First posted
- Aug 18, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Participants will undergo LASIK using Contoura with Phorcides calculation on one eye and LASIK using iDesign calculation on the contralateral eye to correct myopia.
Conditions
- Myopia
- Astigmatism
Interventions
Contoura Topolyzer with PhorcidesDevice
LASIK calculated ablation using Contoura Topolyzer with Phorcides
iDesignDevice
LASIK calculated ablation using iDesign Refractive Studio 2.0
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of eyes with Uncorrected Visual Acuity of 20/16 or better at 6-month Post-OpTime frame: 6-month Post-Op
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Joint Warfighter Refractive Surgery Center at WHASC
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.